SPRY · ARS Pharmaceuticals, Inc.
AI read · Neutral
The AI's read
ARS posted clear top-line progress: U.S. net product revenue of $26.2M, total revenue $33.7M, and U.S. market share doubled to 5%. But operating expenses are huge at $95.1M and management only expects cash-flow breakeven by end-2027. The market reacted violently, down ~14.9% today, signaling investors are focused on burn and execution risk. That gap between revenue growth and cash burn makes the story binary: execute the cuts or raise more capital. Our read is cautious. We lean bearish until the >40% H2 expense cuts materialize and provider-driven uptake shows consistent traction.